Logo

Sanofi Receives the US FDA's Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine

Share this

Sanofi Receives the US FDA's Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine

Shots:

  • The US FDA’s approval is based on five P-II & P-III studies assessing MenQuadfi vs licensed quadrivalent meningococcal in ~5000 people aged ≥2yrs. Four studies evaluated MenQuadfi in meningococcal-naïve person and the other study evaluated MenQuadfi in persons prior to immunized with a quadrivalent meningococcal vaccine
  • Meningococcal-naïve person showed 55.4%–97.2% vaccine induced response 30 days following vaccination with MenQuadfi while prior vaccinated group demonstrated 92.2%–98.2% immune response against each serogroup. The company is investigating the vaccine in ongoing P-III study in infants as young as 6wks. of age
  • The approval marks MenQuadfi as the only US FDA approved quadrivalent meningococcal vaccine indicated for person 2-56yrs. of age and older and is the only vaccine that uses tetanus toxoid as a protein carrier

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Trax Retail


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions